SR-202 (PPAR Antagonist): Mechanistic Insights and Research Benchmarks

Executive Summary:
SR-202, developed by APExBIO, is a selective antagonist targeting the nuclear receptor PPARγ, a central regulator of glucose metabolism and adipocyte differentiation (APExBIO). It inhibits TZD-stimulated coactivator recruitment, suppresses PPARγ-driven transcription, and prevents PPAR-dependent adipocyte maturation in vitro. In vivo, SR-202 reduces high-fat diet-induced adipocyte hypertrophy and improves insulin sensitivity in diabetic murine models (Xue et al., 2025). The compound is widely used as a research tool in anti-obesity and type 2 diabetes investigations. No clinical trials have been reported as of June 2024.

Biological Rationale

Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated nuclear receptor that modulates gene expression involved in glucose metabolism, fatty acid storage, and immune cell polarization (Xue et al., 2025). In metabolic tissues, PPARγ activation promotes adipogenesis and enhances insulin sensitivity. Dysregulation of PPARγ signaling is implicated in obesity, insulin resistance, and inflammatory disorders. Selective PPARγ antagonists like SR-202 enable researchers to dissect PPAR-dependent signaling pathways and test hypotheses about metabolic and immunometabolic disease mechanisms. SR-202's selectivity provides an advantage over non-selective nuclear receptor inhibitors, facilitating precise functional studies in both cell-based and animal models.

Mechanism of Action of SR-202 (PPAR antagonist)

SR-202 is a small molecule designated chemically as (S)-(4-chlorophenyl)(dimethoxyphosphoryl)methyl dimethyl phosphate. It binds selectively to the ligand-binding domain of PPARγ, reducing the receptor's capacity to recruit steroid receptor coactivator-1 (SRC-1) in the presence of thiazolidinediones (TZDs) (APExBIO). SR-202 suppresses TZD-induced PPARγ transcriptional activity, thereby inhibiting downstream gene expression linked to adipocyte differentiation and metabolic regulation. In cell culture, SR-202 blocks both hormone- and TZD-induced adipogenic conversion, confirming its functional antagonism of PPARγ. The compound also antagonizes other PPAR family members, but with highest affinity and selectivity for PPARγ. In animal studies, SR-202 administration reduces the development of adipocyte hypertrophy and ameliorates insulin resistance induced by high-fat diets.

Evidence & Benchmarks

• SR-202 inhibits TZD-stimulated recruitment of steroid receptor coactivator-1 to PPARγ in vitro (APExBIO).
• Suppresses TZD-induced transcriptional activation of PPARγ, with significant reduction in reporter gene expression at concentrations ≥1 µM at 37°C, pH 7.4 (APExBIO).
• Antagonizes PPAR-dependent adipocyte differentiation in murine 3T3-L1 cell models, with ≥90% inhibition at 10 µM after 7 days in differentiation media (Related Article 1).
• In vivo, SR-202 reduces high-fat diet-induced adipocyte hypertrophy and plasma TNF-α elevation in wild-type mice (oral, 20 mg/kg/day, 4 weeks) (Xue et al., 2025).
• Improves insulin sensitivity in diabetic ob/ob mice, as measured by glucose tolerance testing and insulin levels (intraperitoneal, 10 mg/kg, 14 days) (Xue et al., 2025).
• SR-202 blocks intestinal macrophage M1 polarization and reverses OA-induced anti-inflammatory effects in IBD models, confirming its utility as a functional PPARγ inhibitor (Xue et al., 2025).

This article extends the mechanistic details provided in SR-202: Mechanistic Precision and Translational Opportunities, specifically by benchmarking quantitative inhibition data and clarifying application boundaries in immune-metabolic assays.

Applications, Limits & Misconceptions

SR-202 is a tool compound for dissecting the PPAR signaling pathway in metabolic, immunologic, and inflammatory research. Its applications include:

• Modeling PPAR-dependent adipocyte differentiation and metabolic pathway modulation (see also: scenario-based best practices).
• Testing hypotheses about PPARγ’s role in insulin resistance, type 2 diabetes, and obesity (see related: macrophage polarization).
• Studying immune-metabolic crosstalk, particularly in disease models involving macrophage polarization (e.g., IBD, as shown by Xue et al., 2025).

Common Pitfalls or Misconceptions

• SR-202 is not clinically approved and should not be used for therapeutic purposes in humans.
• The compound's antagonism is selective but not exclusive to PPARγ; off-target effects on other nuclear receptors are possible at high concentrations.
• Long-term storage of SR-202 solutions is not recommended; solid form should be kept desiccated at room temperature (APExBIO).
• SR-202 does not reverse established obesity or restore insulin sensitivity in all in vivo models; efficacy depends on dose, duration, and metabolic context (Xue et al., 2025).
• Results obtained with SR-202 may not fully extrapolate to human clinical physiology due to species differences.

Workflow Integration & Parameters

SR-202 (SKU: B6929) is supplied as a white solid with a molecular weight of 358.65 g/mol and chemical formula C₁₁H₁₇ClO₇P₂. It is soluble in DMSO, ethanol, and water at concentrations ≥50 mg/mL. For in vitro studies, recommended working concentrations range from 0.1–10 µM, with incubation at 37°C and pH 7.2–7.4. In vivo studies typically employ dosing regimens from 10–20 mg/kg/day, administered intraperitoneally or orally, depending on the model (product page). Always prepare fresh solutions and avoid prolonged storage of reconstituted compound. For best results in cell-based assays, pre-incubate SR-202 with differentiation media or ligand stimulation cocktails.

For detailed troubleshooting and protocol optimization, consult SR-202 (PPAR antagonist): Scenario-Driven Best Practices, which provides scenario-based guidance for assay design and reproducibility.

Conclusion & Outlook

SR-202 provides researchers with a robust, selective PPARγ antagonist to interrogate the molecular drivers of adipocyte differentiation, insulin resistance, and immune-metabolic crosstalk. Evidence from in vitro and in vivo studies demonstrates its utility in modeling metabolic disorders and inflammatory disease mechanisms. While SR-202 is not intended for clinical use, its application in preclinical research continues to inform anti-obesity drug development and type 2 diabetes research. Future studies may further clarify SR-202’s selectivity profile and expand its use in emerging disease models. For ordering and product specifications, visit the SR-202 (PPAR antagonist) product page at APExBIO.